T
Thomas Martin
Researcher at University of California, San Francisco
Publications - 311
Citations - 17918
Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.
Papers
More filters
Journal ArticleDOI
S184: evaluating teclistamab in patients with relapsed/ refractory multiple myeloma following exposure to other b-cell maturation antigen (bcma)-targeted agents
Cyrille Touzeau,Amrita Krishnan,Philippe Moreau,A. Perrot,S. Usmani,Salomon Manier,Mario Michele Cavo,Carmen Martínez-Chamorro,A. Nooka,Thomas Martin,Lionel Karlin,Xavier Leleu,N. Bahlis,Britta Besemer,Lixia Pei,Rodrido Luiz Costa Verona,Suzette Girgis,Clarissa M. Uhlar,Rachel Kobos,Alfred L. Garfall +19 more
TL;DR: The MajesTEC-1 study as discussed by the authors evaluated the effectiveness of teclistamab in patients with relapsed/ refractory multiple myeloma (RRMM) previously treated with ≥3 prior lines of therapy (LOT).
Journal ArticleDOI
High Throughput NPY-Venus and Serotonin Secretion Assays for Regulated Exocytosis in Neuroendocrine Cells.
TL;DR: Two assays to measure dense core vesicle (DCV) exocytosis-mediated cargo secretion in neuroendocrine cells are described and successfully used for a high throughput siRNA screen and to validate hits identified from the screen.
Journal ArticleDOI
An IPL-V Technique for Simulation Programs
Frank B. Baker,Thomas Martin +1 more
TL;DR: The present paper describes a pseudo-code system and an interpreter both using IPL-V (Newell, 1964) which the writers offer as a reasonable solution to this technological problem.
Journal ArticleDOI
Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex
Swetha Kambhampati,Sandy W. Wong,Thomas Martin,Jeffrey L. Wolf,Priya Choudhry,William J. Karlon,Arun P. Wiita,Nina Shah +7 more
TL;DR: It is hypothesize that azacitidine, by upregulating the expression of CD38, can potentially increase the ADCC and efficacy of daratumumab on multiple myeloma cells and help reverse darumumab resistance.
Journal ArticleDOI
P961: ciltacabtagene autoleucel, a bcma-directed car-t cell therapy, in patients with relapsed/refractory multiple myeloma: 2-year post lpi results from the phase 1b/2 cartitude-1 study
Yi Lin,Thomas Martin,J. Berdeja,Andrzej Jakubowiak,M. Agha,Adam E. Cohen,Abhinav Deol,Myo Htut,Alexander M. Lesokhin,Nikhil C. Munshi,Elizabeth O'Donnell,C. Jackson,Tzu-min Yeh,Avijit Banerjee,Edurne Pardo Zudaire,Deepu Madduri,C. Zhou,Lida Bubuteishvili Pacaud,S. Usmani,Sundar Jagannath +19 more
TL;DR: Ciltacabtagene autoleucel (cilta-cel) as mentioned in this paper is a CAR-T cell therapy with 2 B-cell maturation antigen (BCMA) targeting single-domain antibodies.